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E-mail: ydj2001@med.cornell.eduAdeno-associated virus (AAV) vector serotypes vary in their
ability to transduce hepatocytes from different species.
Chimeric mouse models harboring human hepatocytes have
shown translational promise for liver-directed gene therapies.
However, many variables that influence human hepatocyte
transduction and transgene expression in such models remain
poorly defined. Here, we aimed to test whether three experi-
mental conditions influence AAV transgene expression in
immunodeficient, fumaryl-acetoactetate-hydrolase-deficient
(Fah/) chimeric mice repopulated with primary human he-
patocytes. We examined the effects of the murine liver injury
cycle, human donor variability, and vector doses on hepatocyte
transduction with various AAV serotypes expressing a green
fluorescent protein (GFP). We determined that the timing of
AAV vector challenge in the liver injury cycle resulted in up
to 7-fold differences in the percentage of GFP expressing hu-
man hepatocytes. The GFP+ hepatocyte frequency varied 7-
fold between human donors without, however, changing the
relative transduction efficiency between serotypes for an indi-
vidual donor. There was also a clear relationship between
AAV vector doses and human hepatocyte transduction and
transgene expression. We conclude that several experimental
variables substantially affect human hepatocyte transduction
in the Fah/ chimera model, attention to which may improve
reproducibility between findings from different laboratories.
INTRODUCTION
Adeno-associated virus (AAV) gene therapy targeting hepatocytes is
being pursued for many liver conditions and has progressed into clin-
ical trials for inborn errors of metabolism and hemophilia.1 Several
vectors for treatment of hemophilia by hepatic gene transfer have
entered phase III evaluation.2–4 Diverse serotypes or engineered
capsid variants with liver tropism are utilized in various ongoing clin-
ical trials or are in advanced pre-clinical development. How to opti-
mally predict performance of a specific capsid in human liver geneMolecular Therapy: Methods & Clini
This is an open access article under the CC BY-NC-transfer during pre-clinical development remains a challenge. Hepa-
tocytes from different species vary in their susceptibility to AAV vec-
tor transduction and transgene expression. This has limited the value
of rodent studies in predicting AAV liver gene therapy responses in
humans. Non-human primates are expected to be a better predictor
but also have limitations in mimicking human gene therapy.5 While
investigating AAV vector transduction of human hepatocytes holds
potential to better model clinical gene therapy, in vitro studies are un-
likely to predict in vivo efficacy. Hence, methods to populate mice
with human hepatocytes were developed to enable studies on in vivo
transduction of human hepatocytes.
Liver chimeric mice allow for the study human hepatocytes in labora-
tory animals. In these xenograft models, primary human hepatocytes
(PHHs) are transplanted into immunodeficient mice with a form of
murine liver injury.6 Exploiting the ability of healthy hepatocytes to
proliferate in response to liver damage, the murine liver injury in
these models drives the engraftment and proliferation of human he-
patocytes. There are several forms of murine liver injury that can
result in high humanization. The two most widely used models are
urokinase-plasminogen activator (uPA) transgenic lines7 and fu-
maryl-acetoactetate-hydrolase-deficient (Fah/) lines.8–10 Injury in
the latter model is regulated by the intermittent withdrawal of 2-(2-
nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC, or
nitisinone), otherwise called NTBC cycling.11 In addition to liver
injury, a second requirement shared between liver chimeric mouse
models is an immunodeficiency to prevent xenorejection. While mu-
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Table 1. PHH Donor Characteristics
Name Vendor Lot ID Gender Age (Years)
Mean Peak
hAlb (mg/mL)
PHH1 Celsis AWG male 6 1,498
PHH2 TRL (Lonza) 4129 male 1 3,963
PHH3 TRL (Lonza) 4188 female 1 11,669
PHH4 TRL (Lonza) 4131 female 48 5,836
PHH5 TRL (Lonza) 4145 male 2 4,341
PHH6 TRL (Lonza) 4069 male 30 3,321
PHH7 Becton Dickinson HFCP940 female 2 629
PHH8 BioIVT GEB male 48 797
www.moleculartherapy.orgthese models, the severely immunodeficient Fah/ non-obese dia-
betic (NOD) Rag1/ Il2rgnull (FNRG) background improves human-
ization over less severely immunodeficient Fah/ mice (Y.P.d.J., un-
published data).12,13 Human chimerism in these models strongly
correlates with the level of humanmarkers inmouse serum, and, typi-
cally, human albumin (hAlb) is quantified to determine humaniza-
tion levels.14–16 In our laboratory, FNRG mice typically reach peak
hAlb serum levels 3–4 months after PHH transplantation and
NTBC cycling.
In recent years, Fah/ chimera models have been used to study AAV
biology in human hepatocytes. Their uses include the creation of bio-
engineered capsids with superior human hepatocyte transduction
characteristics,5,17,18 assessment of human hepatocyte transduction
comparing different serotypes,19–22 and the correction of human
gene defects.19 All these studies tested a number of different AAV se-
rotypes expressing a green fluorescent protein (GFP); and while
several studies used similar AAV serotypes, results substantially
diverged not only as to the percentage of transduced human hepato-
cytes but also with regard to serotype hierarchies. This may be due to
the fact that each study used different PHH donors and that several
other experimental parameters also varied or were not clearly speci-
fied. Not knowing to what extent experimental parameters affect hu-
man hepatocyte AAV transduction limits the generalizability of re-
sults from Fah/ chimera studies. We, therefore, set out to
quantify the effects of three experimental conditions on human hepa-
tocyte transduction with a limited number of AAV serotypes express-
ing GFP. We tested how NTBC cycling affects human hepatocyte
GFP expression, quantified the variability between PHH donors,
and studied vector dose responses.Figure 1. The Fah–/– Liver Injury Cycle Affects Human Hepatocyte AAV-GFP Ex
(A) Timeline outlining the creation of human liver chimeric mice, challenge with AAV-GF
primary human hepatocyte; FNRG, Fah/ NOD Rag1/ Il2rgnull; NTBC, nitisinone; hu
challenge and hepatocyte harvest protocols in huFNRGmice. AAV vectors were injected
short 2-day interval off (“medium”), or off the protective drug NTBC for 3 days (“poor”).
challenged with various AAV-GFP vectors. Mice are from independent experiments.
challenge protocols. Symbols represent individual mice; black bar represents the mea
centage GFP+ hepatocytes of the mean of the “efficient” protocol for each serotype. Sym
were calculated by Mann-Whitney test.
Molecular TheRESULTS
Murine Liver Injury Affects AAV Transgene Expression in
Humanized FNRG Mice
Maintenance of the human hepatocyte graft in the FNRG model re-
quires ongoing NTBC cycling. Here, we sought to investigate whether
NTBC cycling affects AAV-GFP transduction of the human graft.
We compared the timing of vector challenge in relationship to how hu-
manized FNRG (huFNRG) mice were cycled. A schematic illustrates
the workflow of these experiments in Figure 1A. PHH donor 1
(PHH1) was transplanted into FNRG mice that underwent NTBC
cycling for approximately 3months to reachplateauhAlb serumvalues.
huFNRG mice were then transduced with 1  1011 vector genomes
(VGs) of AAV-GFP at various times of the NTBC cycle (Figure 1B).
Thirteen days later, hepatocytes were harvested from chimeric livers,
andGFP expression in human hepatocyteswas assessed byflow cytom-
etry.21Hepatocyteswere enrichedbydensity centrifugation and stained
for human leukocyte antigen I (HLA-I) and mouse CD81 (mCD81).
After exclusion of doublets and mCD81+ hepatocytes (Figure S1A),
the percentage of GFP+ human hepatocyteswas quantified (Figure 1C).
Comparing three transduction protocols, a similar pattern of GFP+
fractions was observed across several AAV serotypes previously used
in hemophilia gene therapy clinical studies (Figure 1D).5,21,23 AAV
transduction of huFNRGmice thatwere offNTBC (termed “poor” pro-
tocol) resulted in a very low percentage of GFP-expressing human he-
patocytes. When mice were transduced 1 day after NTBC re-introduc-
tion (“medium” protocol), the percentage of GFP-expressing
hepatocytes substantially increased, with a further slight enhancement
when vector administration was preceded by a longer time off NTBC
(“efficient” protocol). When different AAV serotypes were pooled by
transduction protocol as a percentage of the “efficient” protocol for
each serotype, the “medium” protocol resulted in 23% fewer GFP-ex-
pressing human hepatocytes, while the “poor” protocol diminished
the portion of GFP+ hepatocytes by 86% (Figure 1E). These data
show that, in this Fah/ chimera model, the timing of AAV vector
administration in relationship to the NTBC cycle severely affects the
percentage of GFP-expressing human hepatocytes.Variable Transduction between Human Hepatocyte Donors
Clinical trials with liver-directed gene therapies show a range of trans-
gene product plasma levels within study populations. To test whether
hepatocyte susceptibility to AAV transduction differs between indi-
viduals, we transplanted FNRG mice with eight different PHH do-
nors. FNRG livers were humanized to varying degrees, as determined
by mean plateau hAlb levels in mouse sera (Table 1). After peakpression
P, and flow-cytometric analysis of hepatocytes isolated from chimeric livers. PHH,
FNRG, humanized FNRG; mCD81, mouse CD81. (B) Schematic of three AAV-GFP
while mice were 1 day on NTBC after 2 weeks off (“efficient”), on NTBC 1 day after a
(C) Flow cytometry examples of GFP expression on HLA-I+ hepatocytes from mice
(D) GFP+ human hepatocyte percentages by AAV serotype comparing the three
n of group. (E) Mice challenged with various AAV serotypes were graphed as per-
bols represent individual mice; black bar represents themean of group. The p values

















































































































r = -0.42, p=0.30
AAVLK03 vs. hAlb
AAVLK03 vs. AAVSpark100
r = 0.962, 
p=0.0088
Figure 2. Hepatocyte AAV-GFP Expression Varies
between Human Donors
(A) FNRG mice humanized with 8 different PHH donors
were challenged with AAVLK03-GFP, and hepatocyte
GFP expression was quantified by flow cytometry. Sym-
bols represent individual mice; black bar represents the
mean of the group. The p values were calculated by
Mann-Whitney test and depicted when <0.05. (B) Peak
mean hAlb serum levels of groups of FNRG mice trans-
planted with various PHH donors was plotted against
mean percentage of GFP+ human hepatocytes. Symbols
represent means of groups; correlation was calculated by
Pearson test; colors correspond to those in (A). (C) FNRG
mice humanized with 5 PHH donors were challenged with
AAVSpark100-GFP, and hepatocyte GFP expression was
quantified by flow cytometry. Symbols represent individual
mice. (D) Human hepatocyte GFP+ percentages were
compared between AAVLK03-GFP and AAVSpark100-
GFP challenged mice humanized with 5 PHH donors.
Symbols represent mean percentages of groups; corre-
lation was calculated by Pearson test; colors correspond
to those in (A) and (C).
Molecular Therapy: Methods & Clinical Developmenthumanization was reached, huFNRG mice were transduced with 1 
1011 VGs AAV-GFP using the “efficient” protocol (Figure 1B), and
GFP expression in human hepatocytes was quantified by flow cytom-
etry. For AAVLK03, the mean human hepatocyte GFP+ fraction
ranged from 22% for PHH1 to 3% for PHH4 (7.2-fold difference)
(Figure 2A). Within experiments, the GFP expression patterns varied
between animals transplanted with the same donor (Figure S1B). We
then tested whether liver humanization levels correlated with the frac-192 Molecular Therapy: Methods & Clinical Development Vol. 18 September 2020tion of GFP+ hepatocytes using hAlb serum levels
as a surrogate for liver humanization.14–16 For
these eight PHH donors, only a weak negative
correlation between the percentage of GFP+ hu-
man hepatocytes and peak serum hAlb levels
was observed that did not reach statistical signif-
icance (Figure 2B). There was also no relationship
between PHH gender and GFP expression, with
an average 13.6% human GFP+ cells with five
male donors and 12.4% for three female donors
(p = 0.85). Next, a subset of five PHH donors
was used to test donor variability with another
AAV serotype. Mean percentages of GFP+ hu-
man hepatocytes in mice transduced with AAV-
Spark100, an AAV serotype with established hu-
man hepatocyte tropism,23 varied from 3.8%
(PHH5) to 24.1% (PHH7), a 6.2-fold difference
(Figure 2C). For some donors, striking variability
was again observed between mice in individual
experiments (Figure S1C). Individual donors
tended to respond similarly to AAVSpark100
and AAVLK03 administration. Indeed, a
strong correlation between AAVSpark100 andAAVLK03 mean transduction efficiency was observed within the
same PHH donor (Figure 2D). Similarly to AAVLK03, only a very
weak negative correlation was found between hAlb serum levels
and mean GFP+ fractions for AAVSpark100 (r = 0.25, p = 0.69).
These data show that PHH donors vary up to 7-fold in their suscep-
tibility to AAV vectors independent of liver humanization, and indi-
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A wide range of AAV vector doses have been used across animal and
clinical studies, including in human liver chimeric Fah/ mice from
various laboratories. Here, we sought to quantify dose responses in
huFNRG mice using two different readouts on human hepatocytes
isolated from chimeric livers; namely, the amount of vector genomes
per human hepatocyte (VGs) and the fraction of GFP-expressing hu-
man hepatocytes. To quantify VGs focusing primarily on the human
hepatocytes, we needed populations highly enriched for human cells.
Therefore, we generated three groups of retrorsine-preconditioned
huFNRG mice with PHH3,24 which reliably humanizes the majority
of the chimeric livers as determined by hAlb serum values greater
than 10 mg/mL (Figure 3A). Humanization was confirmed by liver
histology. Low-magnification H&E histology showed few small areas
of mouse hepatocytes, which can be identified by increased hematox-
ylin staining compared to human areas (Figure 3B). Humanization
was further confirmed by human-specific nuclear staining for
NuMA1 (Figure 3B).14 These highly chimeric huFNRG mice were
challenged with an AAVLK03 vector, which minimally transduces
mouse hepatocytes.5 Using the “efficient” protocol (Figure 1A),
mice were given three different doses: 2  1010, 1  1011, and 5 
1011 VGs (indicated as low, medium, and high in the graphs in Fig-
ure 3B). Thirteen days later, hepatocytes were isolated from chimeric
livers, and the percentages of human and mouse hepatocytes were
quantified by flow cytometry (Figure 3C). Although mice that
received higher vector doses showed slightly lower human hepatocyte
purity after isolation from chimeric livers (Figure 3D), the large ma-
jority of isolated hepatocytes in all three groups were human. Total
VGs in 1 million hepatocytes was quantified by qPCR, and the VG
number per human hepatocyte was calculated based on flow cytom-
etry purity. Increasing AAV vector doses resulted in higher VG copy
numbers per human hepatocyte. On average, 5, 16, and 73 VGs per
human hepatocyte were observed using the low, medium, and high
AAV vector doses, respectively (Figure 3E). In a second set of exper-
iments, the effect of AAV vector doses on transgene expression was
quantified. To this end, PHH3 huFNRG mice were challenged with
AAV-GFP at two different doses—namely, 1.5  1010 VG (“low”)
and 1  1011 VG (“medium”)—using the “efficient” protocol. The
mean percentages of GFP-expressing human hepatocytes increased
from 3.2% to 9.7% (3-fold) for AAVSpark100 and from 1.4% to
8.3% (5.9-fold) for AAVLK03 (Figure 3F). These data illustrate thatFigure 3. Hepatocyte Transduction with Varying AAV Vector Doses
(A) Serum hAlb levels of groups of huFNRG mice prior to challenge with increasing dos
mean of group, The p values were calculated by Mann-Whitney test. (B) Histology on live
chimerism. Arrows indicate small darker stained areas that contained predominantly mou
left inset shows small human hepatocytes with pale cytoplasm on the right and large mo
inset shows a human-specific nuclear staining, which confirmed the small pale hepato
NuMA1; scale bar, 50 mm). (C) Illustrative flow cytometry plot of hepatocytes isolated
(mCD81). (D) The percentages of human andmouse hepatocytes isolated from huFNRG
Symbols indicate human and mouse hepatocyte percentages from individual mice; blac
test. (E) AAVLK03 vector genomes were quantified by qPCR in 1 million hepatocytes iso
based on purity determined by flow cytometry. Symbols represent individual mice; black
test. VG, vector genomes. (F) Hepatocytes isolated from huFNRGmice challenged with t
Symbols represent individual mice; black bar represents the mean of group. The p valu
194 Molecular Therapy: Methods & Clinical Development Vol. 18 Septeincreasing doses of AAV result in higher VG numbers and more
transgene expression in human hepatocytes isolated from huFNRG
mice.DISCUSSION
Chimeric mouse models are important tools to study AAV transduc-
tion differences between species but have been poorly standardized.
In the Fah/ chimera model literature, human hepatocyte transduc-
tion percentages vary wildly.5,20–22 Furthermore, studies that use
similar serotypes, e.g., for AAV320–22 or AAV8,5,22 show inconsistent
transduction hierarchies. We have now started to define parameters
that cause variability and have not been appreciated in the past. Spe-
cifically to the widely used Fah/ chimeramodel, NTBC cycling sub-
stantially affects transduction rate. This may, in part, explain differ-
ences in efficiency of gene transfer to human hepatocytes between
published studies using the same serotype. After peak hAlb levels
have been achieved, huFNRGmice in our facility continued to require
intermittent NTBC for survival, which differs from immunodeficient
Fah/ mice in other facilities that can be maintained off NTBC.25
Conversely, we have observed the gradual loss of hAlb serum levels
when huFNRG mice were maintained on continuous NTBC for
months. This suggests that the human grafts in maximally huFNRG
mice remain somewhat dynamic, expanding during the times off
NTBC and contracting while on the drug. In immunodeficient
Rag1/ mice challenged with an AAV-hFIX, cycling of mouse hepa-
tocytes after partial hepatectomy did not affect transduction but re-
sulted in lower hFIX levels.26 Whether human hepatocyte prolifera-
tion in the Fah/ chimera model contributes to the substantial
variability in GFP expression observed in this study, and whether
this is affected by dilution of episomal AAV vectors, will require
further investigation. Such studies could become relevant to AAV
vector therapies for pediatric patients and for liver conditions with
active hepatocyte turnover and regeneration.
Second, we observed striking variability between PHH donors in this
study, with up to 7-fold differences in the percentage of GFP-express-
ing hepatocytes. This finding contrasts with our previous conclusion
that donor variability appeared minimal, which was based on only
two donors21 or data by others with few donors.5 PHH donors vary
in their ability to humanize liver chimeric models, with poor donorses of AAVLK03 vector. Symbols represent individual mice; black bar represents the
r tissue from a mouse with serum hAlb level of 20 mg/mL illustrates the high human
se hepatocytes (top panel, H&E staining; scale bar, 2 mm). The higher magnification
use hepatocytes with darker cytoplasm on the left (H&E; scale bar, 50 mm). The right
cytes to be human while larger mouse hepatocytes stained negative (anti-human
from highly humanized mice that were stained for human HLA-I and mouse CD81
mice challenged with varying doses of AAVLK03 and determined by flow cytometry.
k bar represents the mean of group. The p values were calculated by Mann-Whitney
lated from individual mice, and copy number per human hepatocyte was calculated
bar represents the mean of group. The p values were calculated by Mann-Whitney
wo doses of AAVLK03-GFP or AAVSpark100-GFPwere analyzed by flow cytometry.
es were calculated by Mann-Whitney test.
mber 2020
www.moleculartherapy.orgreaching less than 1 mg/mL hAlb or 10% human chimerism. The
possible weak negative correlation that we observed between hAlb
serum levels and GFP+ human hepatocytes suggests that some of
the donor variability may be confounded by a dose effect as proposed
by others.22 Particularly for serotypes that inefficiently transduce
mouse hepatocytes, AAV vector doses per human hepatocyte may
starkly differ between lowly and highly humanized mice. This expla-
nation was hypothesized to account for discrepant AAV transduction
efficiencies in chimeric Fah/ mice humanized to vastly different
levels with two donors in separate laboratories.17 In regular mice,
gender differences in hepatocyte AAV vector expression have been
long known,27 generally showing higher transgene levels in males
than in females. Given the small numbers of PHH donors in this
study, we cannot draw any conclusions regarding gender differences,
particularly since PHHs from both genders were transplanted into fe-
male FNRG animals. Therefore, we now conclude that transduction
efficiency between donors can vary substantially, but choice of donor
does not appear to alter relative performance of one capsid versus
another. Identifying these variables may help improve the consistency
of clinical AAV gene therapies.
Liver-directed gene therapy trials use various AAV serotypes over
wide dose ranges. Transduction efficiencies are deducted from surro-
gate markers in plasma, and no liver tissues have been analyzed to
quantify transduction efficiencies in human liver. Experiments using
Fah/ chimeras have identified natural and engineered AAV sero-
types that better transduce human hepatocytes.5,17,19–22 These have
led to an appreciation of how starkly many serotypes differ in their
ability to transduce human and animal hepatocytes. Using a serotype
that preferentially transduces human over mouse hepatocytes, we
quantified a dose response based on the average number of AAV vec-
tor genomes per human hepatocyte. The percentage of GFP-express-
ing human hepatocytes also increased with higher AAV-GFP doses,
albeit with substantial spread between huFNRG mice and more
than that reported by others.20,22With susceptible PHH donors, there
was striking variability (Figures 2B, 2D, and S1C) with similar pat-
terns. For other donors, the GFP expression pattern varied with indi-
vidual experiments (Figure S1B) and between serotypes (Figure 1C).
Particularly for serotypes that efficiently transduce mouse hepato-
cytes, e.g., AAV8, lowly GFP-expressing human hepatocytes may be
falsely counted positive. This could be due to flow cytometry gating
limitations or other poorly defined mechanisms such as passive trans-
fer from mouse-expressed GFP to the human graft. To better under-
stand the number of vector genomes required for detectable transgene
expression and define the heterogeneity between individual hepato-
cytes, further analyses at the single-cell level are required. Even
then, the translational value of findings from liver chimeras will
remain largely speculative until liver tissue is analyzed from individ-
uals undergoing AAV gene therapies.
Human liver chimeric mouse models are increasingly applied to
address divergent findings between pre-clinical animal models and
clinical studies. Despite their obvious utility for studying human hepa-
tocyte biology in vivo, they come with a number of limitations. TheMolecular Themurine immunodeficiency required to prevent xenorejection pre-
cludes their use in studying lymphocyte responses against AAV vec-
tors. To overcome this limitation, mice dually humanized with hepato-
cytes and a human immune systemhave been created.14,28–30However,
the human immune cells in these models display limited function-
ality,31 and their utility in modeling immune responses against AAV
remains to be shown. Another limitation of these models is that only
hepatocytes are humanized to high chimerism, while non-paren-
chymal (e.g., sinusoidal endothelial, Kupffer) cells remain largely mu-
rine. This complicates studying interactions between hepatocytes and
other liver cells, given the unknown number of species incompatibil-
ities, e.g., receptor/co-receptor expression, signal transduction, and
other intracellular pathways that may affect viral trafficking. Also, we
do not know whether the high degree of immune deficiency alters
cellular processes that impact hepatocyte transduction. In addition to
these biological limitations, various technical hurdles exist to studying
AAV vector biology in these models. The mixture of human and mu-
rine hepatocytes in the mouse liver poses challenges to quantify the
level of AAV transgene product produced by either species. Therefore,
these models have to rely on a combination of markers to identify
transgene production in human hepatocytes. Commonly used read-
outs are immunofluorescence staining of liver tissues and flow cytom-
etry. Although these techniques vary in the absolute percentages, both
generally correlate well with regard to the hierarchy across several
AAV serotypes within individual laboratories.20–22 However, detection
of low-level fluorophore expression using both techniques is limited by
hepatocyte autofluorescence. We have observed subtle variability in
autofluorescence between human hepatocyte populations isolated
from “identical” huFNRGmice. This is particularly striking in the yel-
low-green spectrum (illustrated by gates in Figure 1C), limiting the
detection of hepatocytes expressing low levels of GFP. Despite these
limitations, liver chimera mice are the only practical laboratory ani-
mals to study human hepatocyte biology. Because in vitro studies
poorly predict animal or clinical data for many AAV serotypes, liver
chimera models likely provide value in bridging findings from human
cell culture studies toward clinical trials.
In conclusion we here have quantified several variables that influence
AAV vector expression in chimeric Fah/ mice. In order to further
improve reproducibility, additional experimental conditions that
were previously shown to affect outcomes in other animal models
remain to be tested in chimeric Fah/mice. These include AAV vec-
tor design, including hepatocyte-specific or non-specific promoters,
methodology of AAV vector production,32 vector injection route,33,34
transgene expression over time, and environmental variables such as
rodent chow and microbiome compositions. Evaluating how these
factors affect AAV vector expression in the human graft will improve
reproducibility and may enhance the translational value of liver
chimeric models.
MATERIALS AND METHODS
Human Subjects and Animal Usage
All protocols involving human tissue were reviewed and exempted
under Category 4 by the Rockefeller University Institutional Reviewrapy: Methods & Clinical Development Vol. 18 September 2020 195
Molecular Therapy: Methods & Clinical DevelopmentBoard (New York, NY, USA). All procedures involving mice were in
accordance with the National Institutes of Health (NIH) Guide for the
Care and Use of Laboratory Animals and approved by the Rockefeller
University Institutional Animal Care and Use Committees (protocol
18063)
AAV Vectors
Recombinant AAV (rAAV) vectors were produced by transfection of
human embryonic kidney 293 (HEK293) cells using liposomes. Three
(or two) plasmid DNAs were combined to produce each rAAV sero-
type.35 These plasmids included (1) pAAV-CB-scGFP, containing the
expression cassette (enhanced GFP under transcriptional control of
cytomegalovirus-enhanced chicken beta-actin promoter) flanked by
AAV inverted terminal repeats (ITRs), with one ITRmodified to pro-
duce self-complementary vector genomes; (2) a helper plasmid DNA
containing rep2/cap3 or rep2/cap9; and (3) pHelper plasmid (Invitro-
gen) containing adenoviral helper genes. For rAAV8 packaging, rep/
cap and adenoviral helper genes were combined in a single construct
(pXYZ5 and pDG8, respectively). HEK293 cells were expanded in 15-
cm plates. Ninety micrograms of total DNA (recombinant and
helpers, in equimolar amounts) per plate were applied. Cells were har-
vested 72 h after transfection, and the virus was purified using the io-
dixanol-density protocol.36 The titer of each preparation was deter-
mined by dot blot hybridization.21
Generation of Humanized Mice and AAV Gene Transfer
PHHs were obtained from vendors as shown in Table 1. Mice were
transplanted with cryopreserved PHHs except for PHH3, PHH7,
and PHH8, which were passaged through mice and adoptively trans-
planted into new animals that were preconditioned with retrorsine.24
Under anesthesia with isoflurane, human liver cell suspensions were
injected intrasplenically (0.5  106 to 1  106 cells per mouse) into
FNRG mice that were generated by 13-generation backcross of the
Fah/ allele11 to NOD Rag1/ Il2rgnull animals, provided by M.
Grompe (Oregon Health & Science University) and obtained from
Jackson Laboratories, respectively.12 Zero to 5 days prior to trans-
plantation, mice were cycled off the liver protective drug NTBC (Ye-
curis), as described elsewhere.8 The hAlb levels in mouse sera were
measured by ELISA (Bethyl Laboratories). AAV vectors were injected
through the tail vein at 1  1011 vector genomes per mouse, unless
specified otherwise.
Hepatocyte Isolation and Flow Cytometry
Mice were anesthetized by ketamine/xylazine injection, after which
the inferior vena cava was cannulated with an angiocath (BD Biosci-
ences) for in situ liver perfusion. After perfusion with heparin, the
large liver lobe was tied off in order to prevent its digestion, removed,
and fixed in 10% formalin for immunohistochemistry. The remainder
of the liver was then perfused with PBS with 0.5 mM EDTA, followed
by PBS with 0.05% collagenase. The collagenase-perfused liver lobes
were resected and put over a 100-mm cell strainer before Percoll pu-
rification and fixation in 4% buffered formalin. After permeabiliza-
tion with BD Cytofix/Cytoperm (BD Biosciences), cells were stained
with anti-human HLA-I-APC/Cy7 (BioLegend) and anti-mCD81-PE196 Molecular Therapy: Methods & Clinical Development Vol. 18 Septe(BD PharMingen). Data were acquired on an LSR II Flow Cytometer
(BD Biosciences) and analyzed using FlowJo software. Sequential
gating strategy was as follows: inclusion of hepatocytes by forward/
side scatter, exclusion of doublets, exclusion of mCD81+ cells, and
the inclusion of HLA-I+. The GFP+ fraction was determined as
percent positive of the HLA-I+ population.
Quantification of Vector Genomes in Isolated Hepatocytes
After isolation from chimeric livers and density purification as
described earlier, total hepatocytes were counted. Cell pellets con-
taining 1 million hepatocytes were frozen at 20C until further
processing. Vector copy number per genome was assessed using a
qualified quantitative PCR (qPCR) assay. Briefly, DNA was extracted
using the ZR Genomic DNA Tissue Midi Prep Kit (Zymo Research)
as per the manufacturer’s protocol. DNA was stored at 80C. Sam-
ples were diluted to 200 ng/mL in nuclease-free water and further
diluted to 100 ng/mL with equal volumes of 2 Diluent S (0.002%
Pluronic F-68, 4 ng/mL salmon sperm DNA in nuclease-free water).
Ten microliters or 1 mg DNA was used in the PCR reaction. Quan-
titative real-time PCR was performed using primers and probes tar-
geting the transgene (50-TGAGGAGGCTGAAGACTATGA-30;
reverse primer, 50- CCACAGACCTGATCTGAATGAA-30; and
a probe, 50-56-FAM-TGGATGTGG/ZEN/TGAGGTTTGATGAT
GACA-3IABkFQ-30). ZEN Double-Quenched Probes containing a
50 fluorophore, 30 Iowa Black FQ quencher, and internal ZEN
quencher were ordered through Integrated DNA Technologies. A
linearized plasmid bearing the target-specific sequence was used
for the preparation of a standard curve.
Immunohistochemistry
Immunohistochemistry and H&E staining was performed on
formalin-fixed, paraffin-embedded murine liver tissues using poly-
clonal rabbit NuMA (Abcam) staining performed as described previ-
ously.14 In brief, sections were deparaffinized in xylene (3 changes),
rehydrated through graded alcohols (3 changes 100% ethanol, 3
changes 95% ethanol), and rinsed in distilled water. Antibody incuba-
tion and detection were carried out on a Discovery XT instrument
(Ventana Medical Systems Tucson, AZ, USA) using Ventana’s Re-
agent Buffer and Detection Kit. Heat-induced epitope retrieval was
performed in a 1,200-W microwave oven at 100% power in 10 mM
sodium citrate buffer (pH 6.0) for 20 min. Sections were allowed to
cool for 30 min and then rinsed in distilled water. Endogenous perox-
idase activity was blocked with hydrogen peroxide. Rabbit anti-hu-
man NuMA was diluted in Tris-BSA (25 mM Tris, 15 mM NaCL,
1% BSA [pH 7.2]) and incubated overnight at room temperature. Pri-
mary antibody was detected with goat anti-rabbit horseradish perox-
idase (HRP) conjugated multimer for 8 min. The complex was visu-
alized with 3,3 diaminobenzidine and enhanced with copper sulfate.
Matched immunoglobulin isotype, at equivalent concentration and
diluted in PBS, was used as negative control. Upon completion of
staining, all slides were washed in distilled water, counterstained
with hematoxylin, dehydrated, and mounted with permanent media.
Stained slides were scanned at 40magnification using the Leica Mi-
crosystems SCN 400F Whole Slide Scanner. Images were viewed andmber 2020
www.moleculartherapy.orgcaptured using SlidePath’s Digital Image Hub (Leica Microsystems,
Buffalo Grove, IL, USA).
Statistical Analyses
Groups of animals were compared by unpaired t test, and correlations
were calculated by Pearson’s r, using Prism 8 software (GraphPad).
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